59.98

0.60% -0.455

Biomarin Pharmaceutical Inc (BMRN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$60.43

Aprire:

$60.43

Volume 24 ore:

213.83K

Relative Volume:

0.09

Capitalizzazione di mercato:

$11.53B

Reddito:

$2.95B

Utile/perdita netta:

$523.88M

Rapporto P/E:

22.30

EPS:

2.69

Flusso di cassa netto:

$620.18M

1 W Prestazione:

-1.71%

1M Prestazione:

+5.10%

6M Prestazione:

+3.97%

1 anno Prestazione:

-15.63%

Intervallo 1D:

$59.72

$60.88

Intervallo di 1 settimana:

$58.50

$63.21

Portata 52W:

$50.76

$73.51

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Nome

Biomarin Pharmaceutical Inc

Settore

Healthcare (1111)

Industria

Biotechnology (621)

Telefono

(415) 506-6700

Indirizzo

105 DIGITAL DRIVE, NOVATO, CA

Dipendente

3,040

Cinguettio

Prossima data di guadagno

2026-02-23

Ultimi documenti SEC

BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BMRN Biomarin Pharmaceutical Inc	59.98	11.62B	2.95B	523.88M	620.18M	2.69
VRTX Vertex Pharmaceuticals Inc	471.18	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	773.05	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	731.68	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	323.49	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	295.38	33.09B	5.36B	287.73M	924.18M	2.5229

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-28	Ripresa	Barclays	Overweight
2026-01-20	Aggiornamento	Canaccord Genuity	Hold → Buy
2025-12-03	Downgrade	Leerink Partners	Outperform → Market Perform
2025-11-06	Downgrade	Stifel	Buy → Hold
2025-09-08	Iniziato	H.C. Wainwright	Neutral
2025-09-03	Iniziato	Raymond James	Outperform
2025-07-03	Ripresa	Morgan Stanley	Overweight
2025-02-24	Aggiornamento	Oppenheimer	Perform → Outperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-10-30	Downgrade	William Blair	Outperform → Mkt Perform
2024-10-10	Ripresa	Raymond James	Outperform
2024-08-20	Aggiornamento	Bernstein	Mkt Perform → Outperform
2024-05-17	Downgrade	Robert W. Baird	Outperform → Neutral
2024-05-14	Iniziato	Evercore ISI	Outperform
2023-11-15	Iniziato	Wells Fargo	Overweight
2023-10-23	Aggiornamento	Bernstein	Underperform → Mkt Perform
2023-09-28	Iniziato	Raymond James	Mkt Perform
2023-09-18	Iniziato	UBS	Buy
2023-07-27	Iniziato	Scotiabank	Sector Perform
2023-07-05	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-03-21	Iniziato	Bernstein	Underperform
2023-02-22	Downgrade	Oppenheimer	Outperform → Perform
2023-02-21	Iniziato	Citigroup	Neutral
2023-01-30	Iniziato	BMO Capital Markets	Market Perform
2023-01-18	Iniziato	Canaccord Genuity	Hold
2022-10-31	Aggiornamento	Oppenheimer	Perform → Outperform
2022-07-13	Iniziato	Cantor Fitzgerald	Overweight
2022-06-13	Ripresa	Wedbush	Neutral
2022-04-25	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-11-22	Aggiornamento	William Blair	Mkt Perform → Outperform
2021-10-07	Ripresa	Jefferies	Buy
2021-09-09	Aggiornamento	Stifel	Hold → Buy
2021-06-04	Ripresa	Robert W. Baird	Outperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-04	Ripresa	Guggenheim	Buy
2021-03-01	Aggiornamento	Evercore ISI	In-line → Outperform
2020-08-20	Downgrade	Citigroup	Buy → Neutral
2020-08-20	Downgrade	William Blair	Outperform → Mkt Perform
2020-08-19	Downgrade	Evercore ISI	Outperform → In-line
2020-08-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-08-19	Downgrade	Stifel	Buy → Hold
2020-07-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-07-06	Reiterato	Citigroup	Buy
2020-01-28	Iniziato	BMO Capital Markets	Market Perform
2020-01-27	Iniziato	BMO Capital Markets	Market Perform
2020-01-24	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2019-11-27	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-12	Iniziato	SunTrust	Buy
2019-10-17	Ripresa	BofA/Merrill	Buy
2019-05-23	Ripresa	Citigroup	Buy
2019-04-09	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-08-07	Reiterato	Stifel	Buy
2018-08-03	Reiterato	Stifel	Buy

Mostra tutto

Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie

04:51 AM

Skeletal Dysplasia Market - GlobeNewswire Inc.

04:51 AM

Mar 04, 2026

Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight - Bolsamania

Mar 04, 2026

Elo Mutual Pension Insurance Co Boosts BioMarin Pharmaceutical Holdings - National Today

Mar 04, 2026

Elo Mutual Pension Insurance Co Purchases 22,851 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 04, 2026

Barclays raises BioMarin stock price target to $105 on acquisition By Investing.com - Investing.com UK

Mar 04, 2026

Mar 03, 2026

Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com

Mar 03, 2026

Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan

Mar 03, 2026

The kids are alright: Old drug from BioMarin scores key win in teensSan Francisco Business Times - The Business Journals

Mar 03, 2026

Barclays raises BioMarin stock price target to $105 on acquisition - Investing.com

Mar 03, 2026

BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients - Intellectia AI

Mar 03, 2026

Mar 02, 2026

Truist reiterates Buy on BioMarin stock amid new competition - Investing.com

Mar 02, 2026

BioMarin stock price target raised to $105 by Freedom Capital on margin outlook - Investing.com Nigeria

Mar 02, 2026

Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma

Mar 02, 2026

Cantor Fitzgerald reiterates Overweight on BioMarin stock at $85 - Investing.com

Mar 02, 2026